aurx20240416_8k.htm
false
0001091596
0001091596
2024-04-16
2024-04-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 16, 2024
Nuo Therapeutics, Inc.
(Exact name of Registrant as Specified in Charter)
|
Delaware
|
000-28443
|
23-3011702
|
|
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
|
of Incorporation)
|
File Number)
|
Identification No.)
|
8285 El Rio, Suite 190, Houston, Texas 77054
(Address of Principal Executive Offices) (Zip Code)
(346) 396-4770
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01 Regulation FD Disclosure.
Nuo Therapeutics, Inc. (the “Company”) will not file its Annual Report on Form 10-K by April 16, 2024, as previously expected and as reported on its recently filed Form 12b-25. The principal reason for the delay in filing is to allow the Company’s independent registered public accounting firm to complete and finalize its review of the Company’s audited financial statements for the year ended December 31, 2023. The Company believes the review will be finalized shortly and expects the Form 10-K to be filed no later than April 19, 2024.
Forward-Looking Statements
This Form 8-K contains forward-looking statements, which are based on management’s current expectations or beliefs about the Company’s future plans, expectations, and objectives. These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements including, including statements regarding the Company’s intention to file the Form 10-K by April 19, 2024. Readers of this Form 8-K are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Nuo Therapeutics, Inc.
|
|
| |
|
|
|
| |
|
|
|
| |
By:
|
/s/ David E. Jorden
|
|
| |
|
David E. Jorden
|
|
| |
|
Chief Executive and Chief Financial Officer
|
|
Date: April 16, 2024